Patient-Derived Organoids and Xenografts Uncover Therapeutic Vulnerabilities in Colorectal Signet Ring Cell Carcinomas

Our study establishes PDO and PDX models as robust platforms for studying SRCC and identifying potential therapeutic strategies. Combining FOLFIRI with paclitaxel/vincristine or chloroquine alone inhibits tumor growth and prevents peritoneal metastasis, showing promise for clinical translation. These findings suggest that combining FOLFIRI with intraperitoneal paclitaxel warrants further investigation in phase I clinical trials for patients with SRCC.

Authors

Institutions

Publication Details

Journal
Clinical Cancer Research
Published
2025-01-29
DOI
https://doi.org/10.1158/1078-0432.ccr-24-2329
Citations
8
Primary Topic
Cancer Research and Treatments
Type
article
Field-Weighted Citation Impact
9.86
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Patient-Derived Organoids and Xenografts Uncover Therapeutic Vulnerabilities in Colorectal Signet Ring Cell Carcinomas

Nandini Verma, Nazia Chaudhary, Poonam Gera, Sanjeev Redkar et al.
8 citations
Clinical Cancer Research
Cancer Research and Treatments
9.86
article

Patient-Derived Organoids and Xenografts Uncover Therapeutic Vulnerabilities in Colorectal Signet Ring Cell Carcinomas

Nandini Verma, Nazia Chaudhary, Poonam Gera, Sanjeev Redkar, Sorab N. Dalal, Avanish Saklani, Satishkumar Singh, Vikas Ostwal, Alessandro La Ferlita, Rahul Thorat, Vaishali Kailaje, B Akshaya, Munita Bal, Lalit Sehgal, Mufaddal Khuzema Kazi, Bhagya Shree Choudhary, Nileema Khapare, Showket Yahya, Eeshrita Jog, Afiya Dalwai
article en
8 citations

Abstract

Our study establishes PDO and PDX models as robust platforms for studying SRCC and identifying potential therapeutic strategies. Combining FOLFIRI with paclitaxel/vincristine or chloroquine alone inhibits tumor growth and prevents peritoneal metastasis, showing promise for clinical translation. These findings suggest that combining FOLFIRI with intraperitoneal paclitaxel warrants further investigation in phase I clinical trials for patients with SRCC.

Clinical Cancer ResearchVol. 31(7)
Homi Bhabha National Institute (IN), The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (US), Tata Memorial Hospital (IN), Advanced Centre for Treatment, Research and Education in Cancer (IN), The Ohio State University (US)
Openalex Percentile: Top 2%
Cancer Research and Treatments
9.86
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.